There is no standard therapy for multiple myeloma relapsing after an autotransplant. We compared the outcomes of a second autotransplant (N ¼ 137) with those of an allotransplant (N ¼ 152) after non-myeloablative or reduced-intensity conditioning (NST/ RIC) in 289 subjects reported to the CIBMTR from 1995 to 2008. NST/RIC recipients were younger (median age 53 vs 56 years; Po0.001) and had a shorter time to progression after their first autotransplant. Non-relapse mortality at 1-year post transplant was higher in the NST/RIC cohort, 13% (95% confidence interval (CI), 8-19) vs 2% (95% CI, 1-5, Pp0.001). Three-year PFS and OS for the NST/RIC cohort were 6% (95% CI, 3-10%) and 20% (95% CI, 14-27%). Similar outcomes for the autotransplant cohort were 12% (95% CI, 7-19%, P ¼ 0.038) and 46% (95% CI, 37-55%, P ¼ 0.001). In multivariate analyses, risk of death was higher in NST/RIC recipients (hazard ratio (HR) 2.38 (95% CI, 1.79-3.16), Po0.001), those with Karnofsky performance scoreo90 (HR 1.96 (95% CI, 1.47-2.62), Po0.001) and transplant before 2004 (HR 1.77 (95% CI, 1.34-2.35) Pp0.001). In conclusion, NST/RIC was associated with higher TRM and lower survival than an autotransplant. As disease status was not available for most allotransplant recipients, it is not possible to determine which type of transplant is superior after autotransplant failure.
INTRODUCTION
High-dose chemotherapy followed by autologous hematopoietic cell transplantation is widely used to treat persons with multiple myeloma (MM). However, there is no standard therapy for those who relapse. 1, 2 The outcome of those relapsing after autotransplantation and are also refractory to proteasome inhibitors and immunomodulatory agents is particularly poor. 3 Options for relapsed patients include clinical trials, second autotransplants or an allogeneic stem cell hematopoietic cell transplant. Because of the high morbidity and mortality associated with myeloablative allogeneic transplantation, lower intensity conditioning regimens such as non-myeloablative (NST) or reduced-intensity conditioning (RIC) allogeneic transplants 4 are more commonly used. There are limited data on the outcomes of NST/RIC in persons with myeloma failing an autotransplant. We used the Center for International Blood and Marrow Transplant Research (CIBMTR) database to compare outcomes of a second autotransplant vs NST/RIC allotransplantation in this setting.
PATIENTS AND METHODS

Data source
The CIBMTR is a voluntary working group of 4450 transplantation centers worldwide that contribute detailed data on consecutive allogeneic and autologous transplants to a statistical center at the Medical College of Wisconsin, Milwaukee, WI, USA. Participating centers are required to register all transplants consecutively; compliance is monitored by on-site audits. Patients are followed up longitudinally, with yearly follow-up. Computerized checks for errors, physicians' reviews of submitted data and on-site audits of participating centers ensure data quality. Observational studies conducted by the CIBMTR are performed with a waiver of informed consent and in compliance with Health Insurance Portability and Accountability Act regulations as determined by the institutional review board and the privacy officer of the Medical College of Wisconsin. All CIBMTR centers contribute to the registration data. Research data are collected on subset of registered patients and include detailed disease and pre-transplantation and post-transplantation clinical information.
Patients
The study population comprised MM patients aged o65 years who had relapsed/progressed after a previous autologous transplant and subsequently received NST/RIC allogeneic transplant or a second autotransplant between 1995 and 2008. The age limit of 65 years was used as most transplant centers would not perform full myeloablative allogeneic transplants in patients X65 years.
Recipients of planned tandem transplants (n ¼ 931) were excluded from the study. The following allogeneic transplant recipients were excluded: those receiving NST/RIC for graft failure (n ¼ 15) or second malignancies (n ¼ 4) as well as patients who received cord blood transplants (n ¼ 2).
Definitions
The intensity of conditioning regimens was categorized as RIC or NST using the established consensus criteria. 5 Previously established criteria for categorizing the degree of HLA matching were used for unrelated donor transplants. 6 Study end points and statistical analysis Primary outcomes were non-relapse mortality (NRM), progression/relapse, PFS, and OS after the second transplant. NRM was defined as death from any cause within the first 28 days after transplantation or death thereafter in the absence of relapse/progression. Relapse/progression was defined according to the standard EBMT/IBMTR/ABMTR (European Group for Blood and Marrow Transplantation/International Bone Marrow Transplant Registry/American Bone Marrow Transplant Registry) criteria. Probabilities of NRM and myeloma progression/relapse were calculated using cumulative incidence curves to accommodate competing risks. 7, 8 OS interval was defined as the time from second transplant to death from any cause. PFS interval was defined as the time from second transplant to relapse/ progression or death from any cause whichever occurs first. Patients alive without evidence of disease relapse/progression were censored at last follow-up. Probabilities of PFS and OS were calculated using the KaplanMeier product limit estimate. Other outcomes analyzed included acute and chronic GVHD and cause of death. Acute GVHD was defined and graded based on the pattern and severity of organ involvement using the established criteria. 9 Chronic GVHD was defined as the development of any chronic GVHD based on the clinical criteria. Both of these events were summarized by the corresponding cumulative incidence estimate, with death without development of GVHD as the competing risk.
Associations between patient-, disease-and transplant-related factors and survival were assessed using multivariate Cox proportional hazards regression. 10 The variables considered in the multivariate analysis were: age (o50 vs X50 years), sex, Karnofsky performance score, Durie-Salmon stage, immunochemical subtype of MM, conditioning regimen for second transplant, interval from diagnosis to first transplant, interval from first transplant to relapse/progression, time interval from first to second transplant, and the year of second transplant. Stepwise variable selection at a 0.05 significance level was used to identify covariates. In the model, the assumption of proportional hazards was tested for each variable using a time-dependent covariate and graphical methods. All variables considered in the multivariate analysis satisfied the proportionality assumption. All computations were made using the statistical package SAS version 9.1 (SAS Institute, Cary, NC, USA).
RESULTS
Subject-, disease-, and transplant-related variables Between 1995 and 2008, 152 subjects received NST/RIC (32 from HLA-identical siblings and 120 from HLA-matched unrelated donors) for relapsed/progressive MM after a previous autotransplant (Table 1) . A total of 137 subjects received a second autotransplant in the same setting. Median follow-up of NST/RIC survivors is 30 months (range, 2-98 months) and 29 months for patients who underwent a second autotransplant (range, 3-97 months). The NST/RIC cohort was younger: median age 53 years vs 56 years (P ¼ 0.001). Gender distribution and Karnofsky performance score were similar.
There was a higher proportion of patients with IgG MM in the autotransplantation cohort (P ¼ 0.004). Stage at diagnosis was similar with 58% of patients in Durie-Salmon stage III in both the cohorts.
As expected, conditioning regimens differed between cohorts. Most (85%) recipients of second autotransplant received highdose melphalan alone. Melphalan-containing regimens were used in only 43% of the NST/RIC group. Only 4% of the autotransplant cohort received TBI as part of their conditioning, in contrast to 29% of the NST/RIC.
The amount of missing myeloma-related data-beta-2 microglobulin, albumin and response status before second transplantbetween the two groups was strikingly different, with 25% of the NST/RIC patients having these data available. There was no meaningful way to compare the disease state before transplant in (8) 58 (38) TBI (no Melphalan) ± others the two cohorts. Among autotransplant recipients, 54 (39%) were in CR or PR, whereas 78% of the NST/RIC cohort had missing disease status data. Median interval from diagnosis to first transplant was similar in both the cohorts. In contrast, interval from first transplant to relapse/progression was significantly shorter in the NST/RIC cohort: 12 months (range,o1-61 months) vs 17 months (range, o1-121 months; P ¼ 0.009) in the autotransplant cohort. Interval from first to second transplants was also shorter for the NST/RIC cohort, 23 months (range 6-78 months) vs 30 months (range, 6-122 months; P ¼ 0.014). Between 1995 and 2000, comparable numbers of patients were salvaged with autotransplants and NST/RIC, but between 2001 and 2006 NST/RIC appeared to be favored, while from 2007 to 2008, the trend appeared to reverse itself, favoring autotransplantation. One-half of subjects receiving an autotransplant received maintenance therapy, but only 11% of the NST/RIC group was reported to receive maintenance; comparisons are again confounded by missing maintenance data for 58% of patients in the NST/RIC group. Table 2 demonstrates unadjusted outcomes. Platelet engraftment at 28 and 60 days was inferior in the NST/RIC group. NRM (Figure 1 ) was 13% (95% confidence interval (CI), [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] ) at 1 year for subjects receiving NST/RIC vs 2% (95% CI, 1-5%) for autologous hematopoietic stem cell transplant recipients (Pp0.001). Three-year probabilities of NRM were 14% (95% CI, 9-20) vs 4% (95% CI, 2-8; Pp0.001). Relapse rates differed at 12 months, favoring the autotransplant group, but this difference did not persist long term (Figure 2 ). There was a trend toward better 5-year progression rates in the NST/RIC group. PFS results also favored the autotransplant group, with the most striking differences at 12 and 36 months (Figure 3) . Finally, OS was far superior at all the time points in the autotransplant group (Figure 4) .
Patient outcomes
The multivariate analyses were limited by the quality of data requested in the forms (insufficient cytogenetic and FISH data) and the quality of data provided for the patients in the NST/RIC Patients who underwent NST/RIC from related and unrelated donors had a similar outcome. The PFS and OS were similar at 1, 3 and 5 years (data not shown). The 3-year OS of patients who underwent NST/RIC from related donors was 19% (95% CI, 7-33) compared with patients whose donors were unrelated, 21% (95% CI, 14-28; P ¼ 0.82). The TRM was also similar, irrespective of donor type (HR 1.077, 95% CI, 0.75-1.54; P ¼ 0.68).
DISCUSSION
The optimal therapy for patients with resistant or relapsed MM after autotransplantation remains unknown. Immunomodulatory agents and proteosome inhibitors have greatly expanded the therapeutic armamentarium against MM, and many patients can benefit from additional therapy after autotransplant relapse. However, the disease eventually progresses or patients develop unacceptable toxicities that limit these therapies. As autotransplantation induces durable remissions with acceptable toxicity, a second autotransplant is also a consideration. Several studies have documented that this approach is feasible, and transplant centers frequently harvest enough stem cells for two transplants in preparation for a second autotransplant upon MM progression or relapse. [11] [12] [13] [14] [15] [16] [17] Other investigators prefer the use of allogeneic transplantation, because the graft is free of tumor and has the potential to induce a graft-vs-MM effect. [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] As the morbidity and mortality associated with myeloablative allogeneic transplantation is high, most centers have relied on low-intensity conditioning NST/RIC. The aim of our study was to have a better understanding whether one type of transplant was favored for patients with relapse/refractory MM requiring salvage transplantation.
Our data demonstrate that patients who undergo autotransplantation rather than NST/RIC as their second transplant fare better across all measures, including rates of progression. Major limitations of this study are the absence of cytogenetic data and a paucity of other prognostic factors available in the NST/RIC cohort. The autotransplant cohort was of lower risk based on a longer time interval from first autotransplant to relapse.
If one compares these registry data to small series from individual institutions, our NRM is lower. The CIBMTR registry 1-year NRM for RIC/NST was 13% as compared with single institution reporting NRM varying from 11% to 26%. [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] An EBMTR analysis of large number of patients who underwent RIC/NST, most of them after autotransplant failure, reported a NRM of 22%. 29 Our results are remarkable when it is taken into consideration that 90% of the patients in this study underwent unrelated RIC/NST. Despite the lower NRM, both PFS and OS in the current study are lower than what has been reported in other studies: OS (24-74%) and disease-free survival (21-61%). [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] These differences may be, in part, a reflection of patient selection, as most of these studies were from single institutions and had smaller number of patients.
The outcome of patients who underwent second autotransplants in this study is similar to previously published reports despite the fact that we only included patients o66 years of age. [11] [12] [13] [14] [15] [16] [17] In a biological assignment trial comparing patients who underwent tandem autotransplants to patients who underwent autotransplants followed by NSC as their initial therapy for myeloma, the 3-year disease-free survival and OS was similar. 30 However, the NRM was higher in the autologous-NSC arm of the study, as observed in our study.
Our study has several strengths and limitations. Strengths include the large number of patients from multiple centers who contributed cases to this study over a long period of time, reflecting more accurately the practice of transplantation throughout this period. Limitations include the lack of information regarding prognostic factors, including cytogenetics and International Staging System stage, information on maintenance therapy and the disease status at the time of alloHCT. With these caveats in mind, the conclusion from these data is that patients who undergo autotransplants as their second transplant fare better than NST/RIC across all measures, including progression rates and NRM. As disease status was not available for most allotransplant recipients, it is not possible to determine which type of transplant is superior after autotransplant failure. Second transplant for relapsed multiple myeloma CO Freytes et al
